Shrinking Staffs

Biotech now looks to products.

A spate of layoff announcements in June offers further evidence that biotech firms are getting serious about ditching drug discovery in favor of product development, despite the recent excitement over drug product approvals and a healthy run-up in biotech stocks.

News Analysis

Ready or Not

Vive la Differentiation!

» Shrinking Staffs

Double Attack

Bull’s-Eye?

Biotech Buys

Sniffing for SNPs